Search

Your search keyword '"Mismetti, P"' showing total 4,620 results
Start Over "Mismetti, P"

Refine your results

more »

more »

more »

more »

more »

more »

more »
4,620 results on '"Mismetti, P"'

115. Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation.

Author

Jean-Christophe Lega, Laurent Bertoletti, Cyrielle Gremillet, Céline Chapelle, Patrick Mismetti, Michel Cucherat, Denis Vital-Durand, Silvy Laporte, and Meta-Embol Group

Subjects
Medicine, Science
Abstract

AIMS: The well-known limitations of vitamin K antagonists (VKA) led to development of new oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta-analysis was to determine the consistency of treatment effects of NOAC irrespective of age, comorbidities, or prior VKA exposure. METHODS AND RESULTS: All randomized, controlled phase III trials comparing NOAC to VKA up to October 2012 were eligible provided their results (stroke/systemic embolism (SSE) and major bleeding (MB)) were reported according to age (≤ or >75 years), renal function, CHADS2 score, presence of diabetes mellitus or heart failure, prior VKA use or previous cerebrovascular events. Interactions were considered significant at p

Published
2014
Full Text
View/download PDF

117. Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021)

Author

Godon, Alexandre, primary, Tacquard, Charles Ambroise, additional, Mansour, Alexandre, additional, Garrigue, Delphine, additional, Nguyen, Philippe, additional, Lasne, Dominique, additional, Testa, Sophie, additional, Levy, Jerrold H., additional, Albaladejo, Pierre, additional, Gruel, Yves, additional, Susen, Sophie, additional, Godier, Anne, additional, Albaladejo, P., additional, Blais, N., additional, Bonhomme, F., additional, Borel-Derlon, A., additional, Cohen, A., additional, Collet, J.-P., additional, de Maistre, E., additional, Fontana, P., additional, Garrigue Huet, D., additional, Godier, A., additional, Gruel, Y., additional, Godon, A., additional, Ickx, B., additional, Laporte, S., additional, Lasne, D., additional, Llau, J., additional, Le Gal, G., additional, Lecompte, T., additional, Lessire, S., additional, Levy, J.H., additional, Longrois, D., additional, Madi-Jebara, S., additional, Mansour, A., additional, Mazighi, M., additional, Mismetti, P., additional, Morange, P.E., additional, Motte, S., additional, Mullier, F., additional, Nathan, N., additional, Nguyen, P., additional, Pernod, G., additional, Rosencher, N., additional, Roullet, S., additional, Roy, P.M., additional, Schlumberger, S., additional, Sié, P., additional, Steib, A., additional, Susen, S., additional, Tacquard, C.A., additional, Testa, S., additional, Vincentelli, A., additional, Zufferey, P., additional, Boissier, E, additional, Dumont, B, additional, James, C, additional, and Siguret, V., additional

Published
2021
Full Text
View/download PDF

118. Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia

Author

Tacquard, Charles, primary, Mansour, Alexandre, additional, Godon, Alexandre, additional, Godet, Julien, additional, Poissy, Julien, additional, Garrigue, Delphine, additional, Kipnis, Eric, additional, Rym Hamada, Sophie, additional, Mertes, Paul Michel, additional, Steib, Annick, additional, Ulliel-Roche, Mathilde, additional, Bouhemad, Bélaïd, additional, Nguyen, Maxime, additional, Reizine, Florian, additional, Gouin-Thibault, Isabelle, additional, Besse, Marie Charlotte, additional, Collercandy, Nived, additional, Mankikian, Stefan, additional, Levy, Jerrold H., additional, Gruel, Yves, additional, Albaladejo, Pierre, additional, Susen, Sophie, additional, Godier, Anne, additional, Albaladejo, P., additional, Blais, N., additional, Bonhomme, F., additional, Borel-Derlon, A., additional, Cohen, A., additional, Collet, J.-P., additional, de Maistre, E., additional, Fontana, P., additional, Garrigue Huet, D., additional, Godier, A., additional, Gruel, Y., additional, Godon, A., additional, Ickx, B., additional, Laporte, S., additional, Lasne, D., additional, Llau, J., additional, Le Gal, G., additional, Lecompte, T., additional, Lessire, S., additional, Levy, J.H., additional, Longrois, D., additional, Madi-Jebara, S., additional, Mansour, A., additional, Mazighi, M., additional, Mismetti, P., additional, Morange, P.E., additional, Motte, S., additional, Mullier, F., additional, Nathan, N., additional, Nguyen, P., additional, Pernod, G., additional, Rosencher, N., additional, Roullet, S., additional, Roy, P.M., additional, Schlumberger, S., additional, Sié, P., additional, Steib, A., additional, Susen, S., additional, Tacquard, C.A., additional, Testa, S., additional, Vincentelli, A., additional, and Zufferey, P., additional

Published
2021
Full Text
View/download PDF

125. 25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial

Author

Galanaud, Jean-Philippe, Genty-Vermorel, Céline, Barrellier, Marie-Thérèse, Becker, François, Jabbour, Violaine, Blaise, Sophie, Bura-Rivière, Alessandra, Comte, Alexa, Grange, Claire, Guenneguez, Herve, Maufus, Mario, Ouvry, Pierre, Richaud, Cécile, Rolland, Carole, Schmidt, Jeannot, Sevestre, Marie-Antoinette, Verrière, François, Bosson, Jean-Luc, Bosson, Jean-Luc, Pichot, Olivier, Maufus, Mario, Guenneguez, Hervé, Ouvry, Pierre, Di Maio, Anna, Schmidt, Jeannot, Galanaud, Jean-Philippe, Bura-Rivière, Alessandra, Couturaud, Francis, Danguy Des Déserts, Marc, Grange, Claire, Mismetti, Patrick, Barrellier, Marie-Thérèse, Laneelle, Damien, Terriat, Béatrice, Stansal, Audrey, Martin, Myriam, Quashie, Constant, Bonaldi, Mickaël, Lanoye, Patrick, Ponchaux-Crépin, Francine, Berremili, Toufek, Sevestre-Pietri, Marie-Antoinette, Samy-Modeliar, Santhi, Addala, Azeddine, Toffin, Luc, Rouquet, Bruno, Michot-Casbas, Maïlys, Lacaze, Guillaume, Roy, Pierre-Marie, Durant, Cécile, Baldassini-Esquis, Anne-Laure, Cazanave, Alain, Rouvière, Damien, Skolka, Hélène, Salem, Tewfik, Monsallier, Jean-Michel, Roger, Benoit, Tra, Thien-Quang, Kalolwa, Mutendi, Diard, Antoine, Lambert, Marc, Taiar, Mebarka, Gaudout, Céline, Ancey, Sylvain, and Jurus, Christine

Abstract

The optimal strength of compression needed to prevent post-thrombotic syndrome (PTS) after a proximal deep vein thrombosis (DVT) is debated. We aimed to assess whether 25 mm Hg elastic compression stockings (ECS) are non-inferior to 35 mm Hg ECS in preventing PTS after a DVT.

Published
2022
Full Text
View/download PDF

128. Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism

Author

Catella J, Bertoletti L, Mismetti P, Ollier E, Samperiz A, Soler S, Surinach J, Mahe I, Lorente M, Braester A, Monreal M, and RIETE Registry

Subjects
anticoagulants, glomerular filtration rate, venous thromboembolism, hemorrhage, urologic and male genital diseases, renal insufficiency
Abstract

Background Detection of severe renal impairment in patients with venous thromboembolism (VTE) is mandatory both for selecting anticoagulant therapy and for evaluating major bleeding risk, increased by severe renal impairment. Objectives To determine whether the Cockcroft and Gault (CG) and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formulas identify severe renal impairment in the same VTE patients presenting the same risk of major bleeding. Patients/Methods We compared clinical characteristics and outcomes during the first 3 months of anticoagulation between VTE patients in the RIETE registry with severe renal impairment according to the CG and/or CKD-EPI formula (estimated glomerular filtration rate 30). Conclusion The CG and CKD-EPI formulas identify different subgroups of patients with severe renal impairment, leading to discordant results in 40.7% of these patients. Irrespective of the formula used for their identification, patients with severe renal impairment have a higher risk of major bleeding under anticoagulant therapy.

Published
2020

129. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery

Author

Samama CM, Laporte S, Rosencher N, Girard P, Llau J, Mouret P, Fisher W, Martínez-Martín J, Duverger D, Deygas B, Presles E, Cucherat M, Mismetti P, and PRONOMOS Investigators

Abstract

BackgroundNonmajor orthopedic surgery of the lower limbs that results in transient reduced mobility places patients at risk for venous thromboembolism. Rivaroxaban may be noninferior to enoxaparin with regard to the prevention of major venous thromboembolism in these patients. MethodsIn this international, parallel-group, randomized, double-blind, noninferiority trial, we randomly assigned adult patients undergoing lower-limb nonmajor orthopedic surgery who were considered to be at risk for venous thromboembolism on the basis of the investigator's judgment to receive either rivaroxaban or enoxaparin. The primary efficacy outcome of major venous thromboembolism was a composite of symptomatic distal or proximal deep-vein thrombosis, pulmonary embolism, or venous thromboembolism-related death during the treatment period or asymptomatic proximal deep-vein thrombosis at the end of treatment. A test for superiority was planned if rivaroxaban proved to be noninferior to enoxaparin. For all outcomes, multiple imputation was used to account for missing data. Prespecified safety outcomes included major bleeding (fatal, critical, or clinically overt bleeding or bleeding at the surgical site leading to intervention) and nonmajor clinically relevant bleeding. ResultsA total of 3604 patients underwent randomization; 1809 patients were assigned to receive rivaroxaban, and 1795 to receive enoxaparin. Major venous thromboembolism occurred in 4 of 1661 patients (0.2%) in the rivaroxaban group and in 18 of 1640 patients (1.1%) in the enoxaparin group (risk ratio with multiple imputation, 0.25; 95% confidence interval, 0.09 to 0.75; P

Published
2020

132. Using 99mTc-(V)-DMSA to follow the vascular calcification process in vascular smooth muscle cells based on pit-1 expression.

Author

Bonnefoy PB, Jacqueroux E, Delavenne X, Roche F, Clotagatide A, Mismetti P, Prevot N, and Perek N

Subjects
Humans, Technetium Tc 99m Dimercaptosuccinic Acid, Muscle, Smooth, Vascular diagnostic imaging, Osteopontin, Vascular Calcification diagnostic imaging, Atherosclerosis
Abstract

Background: Vascular calcification is an established feature of atherosclerosis process. The sodium/phosphate transporter PiT-1 acts as a biosensor in vascular calcification of VSMCs. [ 99m Tc]-Pentavalent dimercaptosuccinic acid ( 99m Tc-(V)-DMSA) was mediated by PiT-1 transporter in tumoral cells and we propose its evaluation in a vascular calcification in vitro model. The aim of this study was to determine if 99m Tc-(V)-DMSA can follow the vascular calcification process in vascular smooth muscle cells (VSMCs) based on PiT-1 expression., Methods: From a rat aortic VSMC cell line (A7r5), we set up a model of calcification within 7 days using a calcifying medium containing a high inorganic phosphate concentration. Phosphocalcic deposits were monitored with Alizarin red and Von Kossa staining and with phase contrast microscopy. PiT-1 expression was evaluated with an immunofluorescence assay and osteopontin expression, with whole cell ELISA assay. 99m Tc-(V)-DMSA uptake was measured in control and calcifying conditions and compared with optical microscopy evaluation., Results: Under hyperphosphatemia conditions, the VSMC cells progressively overexpressed osteopontin protein, PiT-1 transporter, and synthetized mineralized matrix with phosphocalcic deposition. 99m Tc-(V)-DMSA uptake was to 2.8±2.08%DA/mg-protein in control cells and 42±24%DA/mg-protein in calcified cells (P<0.001). PiT-1 inhibition with phosphonoformic acid completely reverse the calcium deposition as well as the 99m Tc-(V)-DMSA uptake. These results demonstrated that 99m Tc-(V)-DMSA in-vitro uptake is mediated by PiT-1 transporter and follow the VSMC calcification process., Conclusions: These preliminary in-vitro results showed 99m Tc-(V)-DMSA uptake follow the phospho-calcic deposition mediated by PiT-1 transporter. This radiotracer may have some potential to detect changes of VSMC metabolism occurring in the atherosclerosis process.

Published
2022
Full Text
View/download PDF

144. Place du pneumologue interventionnel dans la gestion des pleurésies métastatiques

Author

Désage, A.-L., Mismetti, V., Jacob, M., Pointel, S., Perquis, M.-P., Morfin, M., Guezara, S., Langrand, A., Galor, C., Trouillon, T., Diaz, A., Karpathiou, G., and Froudarakis, M.

Abstract

Un épanchement pleural lié à une cause maligne survient chez 20 % de tous les patients atteints de cancer et laisse généralement présager un mauvais pronostic, tout en limitant la qualité de vie du patient. Le diagnostic et la palliation des symptômes est le but de la prise en charge de ces épanchements, tout en minimisant la durée de son hospitalisation pour améliorer sa qualité de vie. Traditionnellement, cela était réalisé par une ponction et/ou une biopsie pleurale suivi d’un drainage thoracique avec l’instillation d’agents sclérosants dans l’espace pleural, en cas de récidive de l’épanchement. Récemment, l’émergence des nouvelles méthodes telles que la biopsie échoguidée, la réalisation de plus en plus courante de la thoracoscopie médicale, ainsi que les cathéters pleureux à demeure ont modifié la prise en charge des pleurésies malignes. L’objectif de cette revue de la littérature est de préciser le rôle du pneumologue interventionnel dans la gestion des pleurésies malignes en se référant aux divers moyens diagnostiques et thérapeutiques qu’il doit posséder actuellement.

Published
2022
Full Text
View/download PDF

148. Pathological Analysis and Clinical Evolution After Radiological Removal of Retrievable Vena Cava Filters.

Author

Annweiler T, Bertoletti L, Grange S, Peoc'h M, Mismetti P, and Barral FG

Subjects
Device Removal adverse effects, Humans, Retrospective Studies, Treatment Outcome, Vena Cava, Inferior diagnostic imaging, Pulmonary Embolism etiology, Vena Cava Filters adverse effects, Venous Thromboembolism etiology, Venous Thrombosis diagnostic imaging, Venous Thrombosis etiology, Venous Thrombosis therapy
Abstract

Objective: Retrievable inferior vena cava filters (IVCF) have been developed because permanent filters have been associated with an increased risk of recurrent deep venous thrombosis. There is no data on the interactions of IVCF with the inferior vena cava (intrafilter thrombi, insertion through the venous wall) even though this may alter the course after retrieval of the IVCF., Methods: A review of 85 consecutive patients undergoing retrieval of IVCF placed at a single center was performed from January 1, 2010 and December 31, 2014. Inferior vena cava filter were examined for presence of intrafilter thrombus at time of retrieval. Filter position and presence of intraluminal thrombus were examined. Patient outcomes, including recurrence of deep vein thrombosis (DVT) and death, were captured at 3 month followup., Results: Eighty five patients were identified, with intrafilter thrombi found in 69 (81%) patients and venous wall fragments found in 75 (88%) patients. However, their presence was not associated with an increased risk of recurrent venous thromboembolism (VTE) or death during follow up., Conclusions: Intrafilter thrombi and venous wall fragments are frequently found in removed IVCF but are not associated with a worse prognosis. They may not modify the therapeutic management of patients.

Published
2022
Full Text
View/download PDF

150. Comparaison du bénéfice-risque à trois ans du dabigatran versus rivaroxaban, en fonction de la dose standard ou réduite, dans la fibrillation auriculaire non-valvulaire, cohorte ENGEL 2 à partir des données du Système national des données de santé avec appariement sur un score de propension haute dimension

Author

Blin, P., primary, Cottin, Y., additional, Dureau-Pournin, C., additional, Abouelfath, A., additional, Lassalle, R., additional, Guiard, E., additional, Balestra, A., additional, Mismetti, P., additional, de Pouvourville, G., additional, Droz-Perroteau, C., additional, Benichou, J., additional, and Moore, N., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results